RAS as an ‘Undruggable’ Drug Target
New therapies are being developed to attack a previously untreatable cancer mutation.
Progress Against Cancer
New therapies are being developed to attack a previously untreatable cancer mutation.
Clinical trials rebound after COVID-19 setbacks, and early treatment leads to significant reduction in anal cancer risk among people with HIV.
As outcomes improved for cancer patients in states that expanded Medicaid, disparities in survival disappeared.
Researchers are investigating how to match specific dietary changes with therapy to impede cancer progression.
DNA sequencing found that in many cases when DCIS recurred, the lesion was unrelated to the first diagnosis, raising questions about how to best treat recurrence.
Expansions in coverage and eligibility through the Affordable Care Act have made Medicaid a lifeline for many people with cancer, but benefits vary from state to state.
Different types of colorectal polyps can be difficult to distinguish, a new AI program improved pathologists' accuracy in a recent study.
Research suggests short bursts of intense calorie restriction could improve treatment response in patients with a range of cancers.
Success of immune checkpoint inhibitors in clinical trials does not always carry over to patients in the clinic.
Metastatic prostate cancer incidence rose after recommendation against routine screening, and FDA approves first PARP inhibitor for early-stage breast cancer for people with inherited BRCA mutations.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More